Recommendations for the treatment of established fungal infections

Internal Medicine Journal

Volumn 38, Issue 6 B, 2008, Pages 496-520

  Thursky, K A ^a,b,d   Playford, E G ^c   Seymour, J F ^d   Sorrell, T C ^e   Ellis, D H ^f   Guy, S D ^a   Gilroy, N ^e   Chu, J ^g   Shaw, D R ^g  

^a ST VINCENT S HOSPITAL   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Antifungal therapy; Aspergillosis; Candidiasis; Consensus guidelines; Invasive mould infections

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; PETHIDINE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; POTASSIUM SPARING DIURETIC AGENT; PYRROLE DERIVATIVE; RIFAMPICIN; STEROID; TACROLIMUS; TERBINAFINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VINCA ALKALOID; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CONSENSUS DEVELOPMENT; CRYPTOCOCCOSIS; DERMATOMYCOSIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; EYE INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; KIDNEY DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; HUMANS; MYCOSES; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS;

EID: 46149088713     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01725.x     Document Type: Review

References (206)

1. Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006 12 : 1508 16.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007 20 : 133 63.
3. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997 24 : 1122 8.
4. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995 20 : 115 25.
5. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999 28 : 1071 9.
6. Nguyen MH, Peacock JE Jr., Morris AJ, Tanner DC, Nguyen ML, Snydman DR et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996 100 : 617 23.
7. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998 104 : 238 45.
8. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001 33 : 1959 67.
9. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in Intensive Care Units: a multicenter, matched-cohort study. J Crit Care 2002 17 : 168 75.
10. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG et al. Candida infections: Outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000 15 : 255 61.
11. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998 27 : 781 8.
12. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006 43 : 25 31.
13. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents Chemother 2005 49 : 3640 5.
14. Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007 119 : 772 84.
15. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004 38 : 161 89.
16. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996 23 : 964 72.
17. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994 331 : 1325 30.
18. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997 16 : 337 45.
19. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 366 : 1435 42.
20. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001 44 : 125 35.
21. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 9.
22. Kuse E-R, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 369 : 1519 27.
23. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007 356 : 2472 82.
24. Betts RF, Rotstein C, Talwar D, Nucci M, Dewaele J, Arnold L et al. Comparison of Micafungin and Caspofungin for Candidemia or Invasive Candidiasis (IC). Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. San Francisco (CA) : American Society for Microbiology 2006 M-1308a.
25. Anaissie E, White M, Uzon O, Singer S, Bodey GP, Matke D et al. Amphotericin B Lipid Compex versus Amphotericin B for Treatment of Invasive Candidiasis: A Prospective, Randomized, Multicenter Trial. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996. San Francisco (CA) : American Society for Microbiology 1996.
26. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003 36 : 1221 8.
27. Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der Hoven B, Spronk P et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006 42 : 1404 13.
28. Herbrecht R, Fohrer C, Nivoix Y. Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 2006 43 : 1083 author reply -4.
29. Sobel JD, Revankar SG. Echinocandins - first choice or first-line therapy for invasive candidiasis? N Engl J Med 2007 356 : 2525 6.
30. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003 3 : 685 702.
31. Lipsett PA. Surgical critical care: fungal infections in surgical patients. Crit Care Med 2006 34 : S215 24.
32. Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007 35 : 1077 83.
33. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrobial Agents Chemother 1995 39 : 40 4.
34. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005 41 : 975 81.
35. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrobial Agents Chemother 2003 47 : 3149 54.
36. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002 34 : 591 9.
37. Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995 21 : 994 6.
38. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002 34 : 600 2.
39. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001 32 : 1249 72.
40. Blumberg EA, Reboli AC. Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis 1996 22 : 462 6.
41. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001 32 : 1713 7.
42. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989 149 : 2226 8.
43. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural histology, and etiology. Medicine 2003 82 : 187 202.
44. Oude Lashof AML, Donnelly JP, Meis JFGM, van der Meer JWM, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003 22 : 43 8.
45. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000 37 : 169 79.
46. Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000 31 : 458 63.
47. Smego RA Jr., Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984 6 : 791 801.
48. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000 182 : 274 82.
49. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003 37 : 728 32.
50. Pagano L, Caira M, Falcucci P, Fianchi L. Fungal CNS infections in patients with hematologic malignancy. Expert Rev Anti Infect Ther 2005 3 : 775 85.
51. Bisbe J, Miro JM, Torres JM, Latorre X, Alia C, Amaral M et al. Diagnostic value of serum antibody and antigen detection in heroin addicts with systemic candidiasis. Rev Infect Dis 1989 11 : 310 5.
52. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, Sopena B, de la Fuente J, Ocampo A et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998 27 : 1130 3.
53. Barza M. Treatment options for candidal endophthalmitis. Clin Infect Dis 1998 27 : 1134 6.
54. del Palacio A, Cuetara MS, Ferro M, Perez-Blazquez E, Lopez-Sana JA, Roiz MP et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 1993 36 : 193 9.
55. Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995 119 : 477 81.
56. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995 20 : 657 64.
57. Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003 121 : 735 7.
58. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006 34 : 857 63.
59. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995 21 : 28 34 5 6.
60. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000 31 : 499 508.
61. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007 4 : e21.
62. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001 33 : 690 9.
63. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005 40 : 1756 61.
64. Shelburne SA 3rd., Darcourt J, White AC Jr., Greenberg SB, Hamill RJ, Atmar RL et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 40 : 1049 52.
65. Ellis D, Chen S, Sorrell TC. Impact of antifungal resistance in Australia. Microbiol Aust 2007 28 : 171 5.
66. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997 337 : 15 21.
67. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004 363 : 1764 7.
68. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. Aids 1997 11 : 1463 71.
69. Hamill RJ, Sobel J, El-Sadr W, Johnson P, Graybill JR, Javaly K et al. Randomized double-blind trial of ambisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 1999 39 : 489.
70. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996 22 : 315 21.
71. Joly V, Aubry P, Ndayiragide A, Carriere I, Kawa E, Mlika-Cabanne N et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996 23 : 556 62.
72. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, Papanaoum K et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995 20 : 611 16.
73. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990 113 : 183 7.
74. Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998 26 : 1362 6.
75. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000 30 : 710 8.
76. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis 1996 22 Suppl 2 : S154 60.
77. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000 30 : 47 54.
78. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J Infect Dis 1994 170 : 238 42.
79. Menichetti F, Fiorio M, Tosti A, Gatti G, Bruna Pasticci M, Miletich F et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996 22 : 838 40.
80. Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J Med Assoc Thai 2003 86 : 293 8.
81. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003 36 : 1122 31.
82. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005 56 : 745 55.
83. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007 45 : 76 80.
84. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005 43 Suppl 1 : S49 58.
85. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 32 : 358 66.
86. Stergiopoulou T, Meletiadis J, Roilides E, Kleiner DE, Schaufele R, Roden M et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007 127 : 349 55.
87. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006 119 : 527.e17 e24.
88. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007 153 : 1677 92.
89. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004 101 : 1594 600.
90. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007 110 : 1303 6.
91. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002 100 : 4358 66.
92. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transpl 2004 34 : 115 21.
93. Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transpl 2002 29 : 15 9.
94. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab Br J Haematol 2006 132 : 3 12.
95. Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991 28 Suppl B : 1 16.
96. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 15.
97. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcomes. Clin Infect Dis 2005 41 : 1448 52.
98. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002 45 : 406 7.
99. Coleman JM, Hogg GG, Rosenfeld JV, Waters KD. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery - case report and review of the literature. Neurosurgery 1995 36 : 858 63.
100. Sanchez C, Mauri E, Dalmau D, Quintana S, Aparicio A, Garau J. Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis?. Clin Infect Dis 1995 21 : 1485 7.
101. Ruhnke M, Kofla G, Otto K, Schwartz S. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007 21 : 659 76.
102. Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Hematol 2004 83 Suppl 1 : S42 4.
103. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990 12 : 1147 201.
104. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 2002 7 : 242 56.
105. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990 12 : 308 29.
106. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002 35 : e120 7.
107. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001 322 : 579 82.
108. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004 54 : 803 8.
109. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998 103 : 205 12.
110. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002 35 : 359 66.
111. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E et al. Liposomal amphotericin B as initial therapy for invasive mould infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 44 : 1289 97.
112. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001 111 : 528 34.
113. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999 29 : 1402 7.
114. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.
115. Candoni A, Mestroni R, Damiani D, Tiribelli M, Michelutti A, Silvestri F et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005 75 : 227 33.
116. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
117. Hof H. A new, broad-spectrum azole antifungal: posaconazole - mechanisms of action and resistance, spectrum of activity. Mycoses 2006 49 Suppl 1 : 2 6.
118. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 59.
119. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 346 : 225 34.
120. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transpl 2007 40 : 451 6.
121. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transpl 2007 39 : 425 9.
122. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005 8 : 344 58.
123. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004 39 : 743 6.
124. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 50 : 1570 2.
125. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005 40 : 1762 9.
126. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 2006 43 : 1449 55.
127. Brodoefel H, Vogel M, Hebart H, Einsele H, Vonthein R, Claussen C et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. AJR Am J Roentgenol 2006 187 : 404 13.
128. Miceli MH, Maertens J, Buve K, Grazziutti M, Woods G, Rahman M et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007 110 : 112 20.
129. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 26 : 1383 96.
130. Sobel JD. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Clin Infect Dis 2004 39 Suppl 4 : S224 7.
131. van't Wout JW, Novakova I, Verhagen CA, Fibbe WE, de Pauw BE, van der Meer JW. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991 22 : 45 52.
132. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003 37 Suppl 3 : S188 224.
133. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 39 : 797 802.
134. Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005 103 : 2334 7.
135. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003 98 : 292 9.
136. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 53 : 337 49.
137. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006 173 : 707 17.
138. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004 10 Suppl 1 : 31 47.
139. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004 17 : 517 25.
140. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004 350 : 950 2.
141. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004 39 : 584 7.
142. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001 45 : 3487 96.
143. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002 46 : 1581 2.
144. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002 46 : 2310 2.
145. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002 46 : 1032 7.
146. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006 50 : 126 33.
147. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006 42.e61 5.
148. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003 51 : 45 52.
149. Keating GM. Posaconazole. Drugs 2005 65 : 1553 67 68 9.
150. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad, II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005 5 : 775 85.
151. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 2006 43 : 1580 4.
152. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005 41 : 521 6.
153. Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in
154. Cooley L, Spelman D, Thursky K, Slavin MA. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 2007 13 : 1170 7.
155. Guarro J, Kantarcioglu AS, Horre R, Rodriguez-Tudela JL, Cuenca Estrella M, Berenguer J et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 2006 44 : 295 327.
156. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004 10 : S48 66.
157. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004 42 : 4419 31.
158. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001 39 : 954 8.
159. Linares MJ, Charriel G, Solis F, Rodriguez F, Ibarra A, Casal M. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol 2005 43 : 250 3.
160. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002 46 : 62 8.
161. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003 47 : 106 17.
162. Slavin MA, Szer J, Grigg AP, Roberts AW, Seymour JF, Sasadeusz J et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004 34 : 192 200.
163. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000 44 : 470 2.
164. Meletiadis J, Mouton JW, Meis JF, Verweij PE. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect 2000 6 : 336 7.
165. Munoz P, Marin M, Tornero P, Martin Rabadan P, Rodriguez-Creixems M, Bouza E. Successful outcomes of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000 31 : 1499 501.
166. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti-Infect Ther 2004 2 : 485 97.
167. Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole: a case report. J Neurosurg 2005 103 : 83 7.
168. O'Doherty M, Hannan M, Fulcher T. Voriconazole in the treatment of fungal osteomyelitis of the orbit in the immunocompromised host. Orbit 2005 24 : 285 89.
169. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002 34 : 1648 50.
170. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003 98 : 315 9.
171. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004 10 Suppl 1 : 67 75.
172. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997 90 : 999 1008.
173. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002 35 : 909 20.
174. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004 38 : 1237 42.
175. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003 41 : 3623 6.
176. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1988 158 : 1046 55.
177. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006 43 : 1060 8.
178. Pfaller MA, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006 43 : S3 14.
179. Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 2003 41 : 4898 900.
180. Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transpl 2003 31 : 411 2.
181. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003 37 : 311 3.
182. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006 42 : 1398 403.
183. Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, Lazzarin A. Successful voriconazole therapy of dissemianted Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother 2006 57 : 796 9.
184. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005 41 : 634 53.
185. Gil-Lamaignere C, Roilides E, Mosquera J, Maloukou A, Walsh TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002 46 : 2234 7.
186. Ikinciogullari A, Dogu F, Solaz N, Reisli I, Kemahli S, Cin S et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther Apher Dial 2005 9 : 137 41.
187. Offner F. Hematopoietic growth factors in cancer patients with invasive fungal infections. Eur J Clin Microbiol Infect Dis 1997 16 : 56 63.
188. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transpl 2006 38 : 327 37.
189. Safdar A. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections. Clin Microbiol Infect 2007 13 : 1 4.
190. Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transpl 2007 39 : 157 64.
191. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005 191 : 1180 7.
192. Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001 32 : 1237 40.
193. McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993 17 : 397 404.
194. Padhye AA, Summerbell RC. The dermatophytes. In : Merz WG, Hay RJ, eds. Topley and Wilson's Microbiology and Microbial Infections: Medical Mycology, 10th edn. London : Hodder Arnold 2005 220 43.
195. Berg JC, Hamacher KL, Roberts GD. Pseudomycetoma caused by Microsporum canis in an immunosuppressed patient: a case report and review of the literature. J Cutan Pathol 2007 24 : 431 34.
196. Nir-Paz R, Elinav H, Pierard GE, Walker D, Maly A, Shapiro M et al. Deep infection by Trichophyton rubrum in an immunocompromised patient. J Clin Microbiol 2003 41 : 5298 301.
197. Lowther AL, Somani AK, Camouse M, Florentino FT.k, Somach SC. Invasive Trichophyton rubrum infection occurring with infliximab and long term prednisone treatment. J Cutan Med Surg 2007 11 : 84 8.
198. Raipara V, Frankel S, Rogers C, Nouri K. Trichophyton tonsurans associated tinea corporis infection with the development of Majocchi's granuloma in a renal transplant patient. J Drugs Dermatol 2005 4 : 767 9.
199. Chastain MA, Reed RJ, Pankey GA. Deep dermatophytosis: report of 2 cases and review of the literature. Cutis 2001 67 : 457 562.
200. Ellis D, Watson A. Systemic antifungal agents for cutaneous fungal infections. Aust Prescriber 1996 19 : 72 5.
201. Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995 33 : 775 9.
202. Evans EGV, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. Brit Med J 1999 318 : 1031 5.
203. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Brit J Dermatol 2003 148 : 402 10.
204. Darkes MJM, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 2003 4 : 39 65.
205. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl 2005 35 : 509 13.
206. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007 109 : 1532 5.